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OPTIONS FOR LOW-COST MANUFACTURING AND SAFER CELL THERAPIES 
 
by Melis Keceli 
 
The proposed work aims to overcome the economical and feasibility-related 
limitations of the chimeric antigen receptor therapies by developing an artificial cell 
signaling pathway whose design transforms K562 cells into in vivo living vectors to 
synthesize therapeutic proteins upon engaging diseased cells in the treatment of ovarian 
cancer. There are various advantages of using K562 cells throughout this process. First, 
Food and Drug Administration approves the reinfusion of K562 cells into patients’ 
bodies. Second, K562 cells are more affordable than T lymphocytes, and finally, these 
cells can be easily manipulated with any desired genetic material and can keep the 
expression of engineered genes stable. However, they do not express a chemokine 
receptor, a type of cytokine controlling the traffic of the immune cells to a desired site of 
the body. Therefore, these cells must be manipulated with chemokine receptors to enable 
them to migrate directly towards the tumor microenvironment to prevent harm to the 
healthy parts of the body. For the manipulation of all cells used in this study, lentiviruses 
were produced to transduce them. Nanoluc luciferase reporter was used as an effector 
protein to evaluate whether K562 cells can synthesize these enzymes in situ upon 
interacting with diseased cells. K562 cells lack necessary molecules that would drive 
them to form an immunological synapse to produce engineered proteins. As a result, 
they were not able to  produce the Nanoluc enzyme. On the other hand, this study shows 
that the chemokine system presents an excellent potential for immunotherapies, and it 
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The oldest description of cancer dates back to about 3000 BC and is found in ancient 
Egyptian manuscripts. Cancer is the second leading cause of death, behind heart diseases, 
in the United States, and the World Health Organization (WHO) attributes an estimated 
9.6 million deaths to cancer worldwide (1). Research into the risk factors for developing 
cancer is considered a priority. Several factors have been identified: cancer can be 
hereditary, or it can occur because of ‘lifestyle factors, including but not limited to 
tobacco smoke, alcohol consumption, and excessive sun or radiation exposure (2). 
The treatments currently available for cancer include surgery, chemotherapy, 
radiation therapy, and immunotherapy. The selection of treatment is dependent on the 
type of cancer and its location, as well as how advanced it is. Some patients may receive 
only one type of therapy, while others receive a combination simultaneously or in 
sequence. The treatment goal is to eradicate as many tumor cells as possible while 
minimizing the harm to the surrounding healthy cells. However, all treatments have 
potential disadvantages and have the potential to cause harm. For example, 
chemotherapy, radiation therapy, and surgery may damage nearby tissues or may be 
unable to kill all the cancerous cells. Thus, it should be noted that none of these therapies 
may be able to cure cancer completely (3).   
Immunotherapy is an emerging area of cancer research that shows tremendous 
advantages in relation to increasing survival rates and the maintenance of patients’ life 
quality when compared to the other types of treatments mentioned above (4). 
Immunotherapy is a biological therapy that teaches the body’s immune system to fight 
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cancer. There are two lines of defense of the body against foreign substances: innate 
immunity and adaptive immunity. Innate immunity is the first line of defense and is 
present from birth, protecting the body from infections even before they start. Most 
infections can be stopped by innate immunity. However, if they cannot, the second line of 
defense, adaptive immunity, becomes active. As such, lymphocytes, the key elements of 
adaptive immunity, would recognize pathogens with their cell surface antigens and 
proliferate to clear the body of foreign substances (5,6). Lymphocytes are mainly divided 
into T lymphocytes and B lymphocytes. While B lymphocytes are programmed to 
produce antibodies, T lymphocytes are programmed to recognize antigens and respond to 
them (7). T lymphocytes have T cell receptors (TCRs) on their cell surface that would 
allow them to engage the major histocompatibility complex (MHC) on the target diseased 
cells. MHC is a genetic system that binds peptide fragments of pathogens and expresses 
them on the cell surface to be recognized and destroyed by immune cells. However, many 
cancer cells do not express MHCs on their cell surface as a result of an evolutionary 
mechanism, avoiding immune cells and spreading to other parts of the body (6,8). To 
overcome this limitation, scientists manipulate patients’ T cells with a protein called 
chimeric antigen receptor (CAR). CARs enable T cells to bind cancer cells even though 
they don’t have MHCs on their surface (9).  
In CAR T cell therapy, a patient’s white blood cells are collected, and the T cells are 
separated. These T cells are then genetically engineered in a laboratory to express CARs 
on their cell surface and are then grown into the hundreds of millions to be given to the 
patient by infusion. The CARs enable T cells to bind to the antigens on cancer cells and 
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kill them (10). Since each cancer type has its specific antigen, CARs must be specific and 
generated for each cancer type respectively to attach to the different receptors of different 
cancer cells.  CAR T cell therapy is a process in which each patient’s immune cells are 
meticulously treated and engineered to express specific receptors depending on the 
cancer type. However, Primary T cells are highly challenging to grow in the laboratory as 
they need to be activated first. Given these challenges, CAR T cell therapies are costly 
and not affordable for many cancer patients, even though there are two approved CAR T 
cell therapies by Food and Drug Administration (FDA). The two treatments, Kymriah 
and Yescarta, cost $475,000 and $373,000, respectively (11). As a result of being very 
expensive, a cheaper alternative to CAR T cell therapy must be found to provide more 
affordable and accessible treatments for cancer patients.  
Further to high treatment costs, current protein-based cancer therapies have side 
effects, such as systemic toxicity, and the dose-response relationship varies from patient 
to patient. To overcome these limitations, T cell biofactory technology represents a great 
potential to synthesize and deliver appropriate amounts of therapeutic proteins for cell-
based diseases like cancer, viral infections, and autoimmune diseases. T cell biofactory 
technology refers to developing an artificial cell-signaling pathway whose design 
transforms a T cell into a living vector that would synthesize engineered therapeutic 
proteins during the engagement with the antigen-presenting target cells. Reprogramming 
of a biofactory to recognize different targets depending on the cancer type or disease type 
is also possible.  A previous study performed by Bhatnagar et al. (45) showed that T cell 
biofactory has a great potential for targeting diseased cells with maximal specificity. This 
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technology was first applied to Jurkat cells (12). Jurkat cells, an immortalized line of T 
cells, have all the machinery that Primary T cells have, except they are cancer cells. 
Jurkat cells are preferred for new application evaluation because their culture and growth 
in the laboratory are more manageable compared to Primary T cells. Although this 
system has worked, and Jurkat cells have produced the engineered proteins, it is not 
possible to reinfuse Jurkat cells into the patient’s body as they are cancer cells. Also, 
implementing this system in Primary T cells would cause the therapy to be costly, which 
is unlikely accessible for all cancer patients. Also, for the best results of this therapy, the 
effector cells must migrate directly to the diseased cells. To do this, T cells are 
engineered to express chemokine receptors that drive them to the site of infection in the 
body. Chemokines, being chemotactic cytokines, control the homing, retention, and 
migration of immune cells towards the tumor microenvironment (13). Thus, the 
chemokine system represents a potential target for CAR T cell therapies as it enables 
effector cells to go directly to target cells. 
In order to find a cheaper alternative to CAR T cell therapies, one of the aims of this 
study was to test if K562 cells can be used as a cellular chassis for developing a 
biofactory technology to produce therapeutic proteins for ovarian cancer. It is important 
to note that it is possible to replace the antibodies that recognize antigens and the proteins 
that can be synthesized in situ upon the engagement of effector and target cells, 
depending on the disease type. Therefore, biofactory technology has a great potential for 
targeting different cell-based diseases. The rationale for choosing the K562 cell line is 
that it has been clinically approved to be safely administered to patients with acute 
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myeloid leukemia after being genetically modified, and it is cheaper and easier to expand 
than Primary T cells. As the price of CAR T cell therapies is an obvious barrier, this 
study may result in economic benefits. Another aim of this study was to test the 
hypothesis that Jurkat cells migrate directly to the tumor microenvironment. Neither 
Jurkat nor K562 express chemokine receptors. As a result, these cells may target and 
harm healthy parts of the body after reinfusion. Therefore, to have effector cells migrate 
directly to the diseased site, Jurkat cells were engineered to express appropriate 
chemokine receptors whose corresponding chemokines were produced in the ovarian 
tumor microenvironment. If Jurkat cells successfully migrate towards the tumor cells, the 
same system can be implemented in K562 biofactories in later studies. This 
implementation would provide safer therapy in which K562 biofactories directly migrate 




2 Literature Review 
This literature review first discusses different types of cancer immunotherapy, 
building background information. Second, CAR T cell therapies and their challenges are 
addressed to indicate the need for this study. Third, the importance of forming an 
immunological synapse and chemokine system for T cells’ migration, differentiation, and 
activation is discussed. Finally, different viral gene delivery techniques for delivering 
genetic material to CAR T cells are reviewed. 
2.1 Cancer Immunotherapy 
Immunotherapy, also known as biological therapy, is the fight of our immune cells 
against cancerous cells (4). Dr. William Coley, known as the father of immunotherapy, 
was moved to research immunotherapies for cancerous tumors after a 17-year-old patient, 
who did not recover and died weeks later despite the amputation of the sarcoma. Coley 
documented his successes through experimentation and published case series, achieving 
remission for sarcoma, lymphoma, and testicular cancer. However, his method was met 
with initial skepticism, and other oncologists were concerned about deliberately injecting 
patients with pathogenic bacteria to treat malignant cells (14). 
Since Coley’s early work, immunotherapy has progressed significantly, and there are 
now multiple types of immunotherapies available. One such method is adoptive T cell 
therapy, also known as cellular adoptive immunotherapy or T cell transfer therapy (7). 
There are three types of adoptive T cell therapy; tumor-infiltrating lymphocyte (TIL) 
therapy, engineered T cell receptor (TCR) therapy, and chimeric antigen receptor T cell 
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(CAR T cell) therapy. Researchers have recently begun to incorporate natural killer cells, 
another type of immune cell, for an alternative adoptive therapy (15).  
TIL therapy was pioneered in the late 1980s to treat metastatic melanoma. In this type 
of therapy, T cells are isolated from a patient’s tumor and expanded ex vivo with 
interleukin 2 (IL-2), a type of cytokine that enhances T cells’ activation and contributes 
to their differentiation into effector T cells (15,16). The effector T cells are then infused 
intravenously into the patient’s body. Even though studies show promising results, not 
every patient has T cells recognizing their tumors, meaning such patients’ T cells cannot 
bind to antigens and destroy cancer cells. To address this challenge and support a wider 
range of cancer patients, TCR therapy has been developed. In TCR therapy, patients’ T 
cells are isolated too, but instead of just activation and expansion, doctors and scientists 
can manipulate T cells and target specific tumor antigens. Once manipulated, T cells are 
grown in the laboratory and are then reinfused into the patient’s bloodstream. This 
method provides more personalized treatments compared to TIL therapy (7,15).  
Although these two therapies have led clinical oncologists to expect more significant 
tumor regression, results have been disappointing and below expectations. One 
explanation for the lackluster results may be the downregulation of major 
histocompatibility complex I (MHC-I) on the tumor surface. The downregulation of 
MHCs causes cancer cells not to be recognized and destroyed by T cells. Therefore, 
cancer cells can grow and spread to other parts of the body (8). To have promising results 
from TCR therapy, MHC or human leukocyte antigen complex (HLA complex), a 
chromosomal region with different genes, must present intracellular tumor-related 
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antigens on cancer cells’ surface to TCRs on T cells (5). MHC-I or MHC-II should be 
present on the cancer cells’ surface to be detected or destroyed by immune cells (8). To 
overcome this limitation, scientists equip patients’ T cells with a protein called chimeric 
antigen receptors (CARs). CARs enable T cells to bind to cancer cells despite not having 
MHCs on their surface and enable immune cells to better identify cancer cell antigens. 
Since each cancer type has its specific antigen, each CAR is generated specifically for 
each cancer type. CAR T cells contain extracellular, intracellular, and transmembrane 
regions. Whereas the extracellular region has a single-chain variable fragment (scFv) 
domain to recognize tumor-associated antigens, the intracellular domain is composed of 
immunoreceptor tyrosine-based activation motif (ITAM) of the cluster of differentiation-
3 zeta (CD3ζ), which activates co-stimulatory molecules (9,17).  
2.2 CAR T Cell Therapies 
  CAR is a hybrid antigen receptor, which includes a part of an antibody and a part of a 
TCR. The antibody part is found in the transmembrane domain, and the T cell receptor 
part is found in the intracellular domain. The antibody part of CAR enables it to bind to 
an antigen, and the TCR part helps activate the CAR when encountering antigen-
presenting cells (18). Over the past years, there have been five generations of CAR T 
cells, which have been generated to target a specific protein independent of MHC Class I 
or MHC Class II, which depends upon the type of T cell (either CD8+ or CD4+ T 
lymphocyte, respectively) on an antigen-presenting cell’s surface (9,17).  
In 1993, Eshhar et al. were the first to show the first-generation CARs, consisting of 
scFv extracellular domain as an antigen recognition motif and a cluster of differentiation-
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3 zeta (CD3ζ) ITAM domain as an activation motif. They expected these CARs would 
promote IL-2 secretion upon encountering cancer cells independent of MHC (19). 
However, two years later, Brocker et al. found that resting T cells and effector T cells had 
different signaling capabilities. The chimeric receptor ζ, which would activate T cells, 
expressed by transgenic mice was not sufficient to activate resting T cells. Nevertheless, 
if the T cells were preactivated, the chimeric receptor ζ was able to activate them. Also, 
the activated T cells were able to proliferate and had cytotoxic effects upon encountering 
antigen-presenting cells (20).  
In the late 1990s, Gong et al. conducted a study with patients at different stages of 
prostate cancer. They showed that if T cells were engineered to express the Pz-1 receptor, 
which lyses prostate cancer cells, they could release cytokines and target tumor cells (21). 
Upon completion of these studies (19, 20), it was concluded that the first-generation of 
CAR T cells had insufficient proliferation, secretion of cytokines, and cytotoxic activity 
in vivo (22).  
Going forward, co-stimulatory molecules identified as vital for T cell activation, 
proliferation, and survival were added to second and third-generation CARs. T cell 
activation needs two signals, one from a TCR and the other from a co-stimulatory 
molecule such as CD28. This co-stimulatory molecule improves IL-2 synthesis, a 
cytokine necessary for the T cell stimulation, as proved by Finney et al (23). Thus, the 
absence of co-stimulatory molecules prevents naive T cells' functions, which would lead 
to T cells' anergy (24, 25). The co-stimulatory molecule used to generate the second-
generation CARs is not limited to CD28. Song et al. and Homback et al. demonstrated 
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that CD27 or 4-1BB (CD137) and OX40 (CD134) can also promote T cell proliferation 
and improve CAR T cell function (26,27). The third-generation CARs are different in 
that they are made by combining CD3ζ-CD28-OX40 or CD3ζ-CD28-41BB to enhance 
the CARs' potential in terms of killing and cytokine secreting. This means that the third-
generation CARs have two co-stimulatory molecules rather than just one as in second-
generation CARs (24).  
The fourth-generation CARs, also known as TRUCKs (T cells redirected for antigen‐
unrestricted cytokine‐initiated killing), were generated by adding Interleukin 12 cytokine 
(IL-12) to the base of the second-generation CARs. IL-12 cytokine produced by different 
cells in response to an antigenic stimulation recruits macrophages that would destroy 
bacteria or other harmful microorganisms. Thus, TRUCKs can also treat innate system 
disorders such as viral infections. Studies exploring different cytokines such as IL-7, IL-
15, IL-18, and IL-23 to generate the fourth-generation CARs are still going on. Each has 
different features, but all ultimately aim to enhance T cell functions (28). These 
successive generations of CARs bring high expectations and hope in cancer treatment.  
2.3 CAR T Cell Therapy Challenges 
Over the decades, CAR T cell therapies have been under investigation due to their 
unprecedented and unparalleled results in cancer treatments. Even though many 
investigations aim to use CAR T cell therapies to treat different kinds of cancer, only a 
few have been approved by Food and Drug Administration (FDA). 
Clinical trials of CAR T cell therapies have shown remarkable results in B cell 
malignancies. B cell malignancies include relapsed and refractory chronic lymphocytic 
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leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), 
non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), and acute 
lymphocytic leukemia (ALL). B cell malignancy is a type of cancer formed in B cells. 
This disease causes the formation of many abnormal B lymphocytes that cannot fight 
germs as mature B cells do. B cells have a transmembrane glycoprotein, CD19, on their 
cell surface from early pro-B development to the end of their differentiation into mature 
B lymphocytes. B lymphocyte antigen CD19 is an attractive therapeutic target for CAR T 
cell therapies to treat B cell lymphoma because its expression is restricted to B cell 
lineage (29,30). Kochenderfer et al. treated a patient with advanced follicular lymphoma 
with a combination of chemotherapy and genetically engineered T cell therapy. They 
engineered T cells with retroviral vectors to express anti-CD19 CAR that was able to 
recognize CD19. They reinfused those T cells into the body, and 64% of those expressed 
the CAR as measured by flow cytometry. After nine weeks of the reinfusion, the patient's 
lymphoma showed partial remission, and thirty-six weeks after anti-CD19 CAR 
transduction, CD19+ cells were completely eradicated from their blood (31). After this 
first effective CAR T cell therapy, Kochenderfer et al. reported on the first clinical trial 
with 15 patients with DLBCL by using anti-CD19 CAR T cell therapy. Eight of the 15 
patients showed complete remission, and four of them achieved partial remission. These 
results demonstrated this treatment's broader effectiveness in treating B cell malignancies 
(29,32). 
Based on these successful results, many more studies have been conducted over the 
years, and the first CAR T cell therapy Kymriah, marketed by Novartis, was approved by 
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the FDA in 2017 for children and young adults up to age 25 with relapsed and refractory 
(r/r) ALL, or for adults with r/r DLBCL (33,34). Before the approval of this therapy, 
Maude et al. conducted Phase II ELIANA trial, the first pediatric global CAR T cell 
therapy, with 63 pediatric and young adults with r/r ALL. Upon completing this study, 
they found the overall remission rate as 83% within three months of infusion (35). 
Another study conducted by Schuster et al. was the international Phase II JULIET trial, 
the first multi-center global registration study, with 93 adult patients. The overall 
response rate was 52%, including 40% of complete responses and 12% of partial 
responses (36). One year after the approval, Kymriah was also authorized for use in 
Europe (30). 
 Another CAR T cell therapy, Axicabtagene ciloleucel (AXI-CEL/KTE-C19), 
marketed by Kite as Yescarta, received FDA approval in 2019 for patients with 
aggressive r/r NHL including DLBCL. Locke et al. conducted phase I of the ZUMA-1 
trial to support the KTE-C19 approval. Nine patients were enrolled in this study to 
evaluate the safety and efficacy of anti-CD19 CAR T cells (37). After getting promising 
results from this study, Neelapu et al. conducted phase II with 111 patients who have had 
histologically large B cell lymphoma. Phase II of the ZUMA-1 trial showed an objective 
response rate of 82% and a complete response of 54%. These results have made doctors 
and scientists believe that Axicabtagene ciloleucel provides clinical benefits to patients 
(38). 
Despite the successful results for ALL patients, there are still challenges to overcome 
for CAR T cell therapies. Today, two main challenges remain: selecting the right antigen 
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to be targeted and ensuring T-cell migration to the solid tumor. An ideal antigen for solid 
tumors should be highly expressed on them and remain unexpressed on other vital 
tissues. As solid tumors' antigens may also be found on healthy tissues, it is very hard to 
find the specific antigen for solid tumors (29,30). 
Lack of a specific target antigen for solid tumors may cause on-target off-tumor 
toxicity. This complication occurs when CAR T cells attack healthy cells that express the 
intended target antigen. Although this toxicity may be clinically manageable and may not 
be considered a life-threatening side effect for B cell malignancies, it is yet another 
challenge for solid tumors (30). For instance, Morgan et al. discuss a case that came to a 
catastrophic end. A 39-year-old female patient with metastatic colon cancer was infused 
with the CAR T cells targeting HER2 (ERBB2) antigen, which is overexpressed in the 
tumor microenvironment of some cancer types, including breast, colon, and ovarian 
cancers. After the infusion, the patient's epithelial cells of the lung were attacked by the 
CAR T cells, and she died five days after the infusion. Her death was attributed to the 
low levels of HER2 in the epithelial cells (39). Since this fatal event, scientists have been 
trying to find other cancer markers that are safer and more effective for solid tumors. One 
such marker is ICAM-1 (intercellular adhesion molecule-1), and it bears CARs with 
micromolar affinity rather than nanomolar affinity. Since ligands with nanomolar affinity 
would bind more tightly to the proteins when compared to those of micromolar affinity, 
ICAM-1 markers are expected not to bind to healthy cells tightly. The affinity of CARs 
influences cytokine release. Thus, a reduced affinity targeting strategy would allow rapid 
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tumor elimination while preventing the toxicity that would occur because of tight binding 
(40). 
The most frequently reported life-threatening toxicity associated with CAR T cell 
therapy is cytokine release syndrome (CRS). After the infusion of CAR T cells into the 
bloodstream, the number of cytokines, IFNγ, TNFα, and IL-2, in the body rises and 
causes CRS. The symptoms of CRS include high fever, nausea, headache, and or mild to 
severe tachycardia (30,41). Another CAR T cell-mediated fatal toxicity is neurotoxicity, 
co-occurring or after CRS. Some common manifestations of neurotoxicity are headache, 
confusion or delirium, and rarely acute cerebral edema (41,42). To date, both 
neurotoxicity and CSR occur in many patients who are treated with CD-19 CAR T cell 
therapy (30). Teachey et al. measured cytokine numbers in 51 patients’ bloodstream after 
receiving CD-19 CAR T cell therapy for ALL. They realized a peak in the number of 24 
cytokines including IFNγ and IL-6 (43). To identify risk factors of neurotoxicity resulting 
from CD-19 CAR T cell therapy, Gust et al. studied 133 patients’ neurological adverse 
events after the infusion. Fifty-three patients experienced neurological adverse events, 
from mild symptoms to death. Also, the majority of the 53 patients had CRS as well. 
These results led researchers to that CRS causes a higher risk of neurotoxicity 
development (44). 
2.4 Immunological Synapse 
To activate the cell signaling pathway developed for this study, the formation of an 
immunological synapse between the effector cells and the antigen-presenting cells 
(APCs) is vital. An immunological synapse (IS) is a junction between APCs and 
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lymphocytes, such as T cells, where the interaction of T cell receptors (TCRs) and 
peptide major histocompatibility complexes (MHCs) occurs (46,47). IS is also known as 
a supramolecular activation cluster (SMAC), and it is formed of three major 
compartments: central SMAC (cSMAC), peripheral SMAC (pSMAC), and distal SMAC 
(dSMAC) (46,48). The external ring, dSMAC, is composed of large membrane 
glycoproteins such as CD43 and CD45 (48). It is the site where TCR microclusters (MC) 
first engage with peptide-MHCs. Once TCR-MCs are formed, they are translocated 
toward pSMAC, which is formed of integrins and the proteins involved in cell adhesion, 
such as lymphocyte function-associated antigen-1 (LFA-1), the cytoskeletal protein talin, 
and ICAM-1 (49,50). The inner circle, cSMAC, is the center area of this structure in 
which TCRs, CD2, CD4, CD8, CD28, protein kinase Cθ (PKCθ), and lymphocyte-
specific protein tyrosine kinase (Lck) are concentrated (48,51). The proteins TCRs, CD2, 
CD4, CD8, and CD28 are expressed on the surface of immune cells (such as T cells), 
while Lck and PKCθ are expressed inside T cells. Whereas Lck associates with the 
cytoplasmic tails of CD4 and CD8, PKCθ plays a key role in the T cell activation. Each 
molecule mentioned here has an essential part in the function of IS, which integrates 
antigens, adhesion molecules, and co-stimulatory molecules. The co-stimulatory 
receptors CD4, CD8, and CD28 synergize to activate T cells, while the interaction 
between LFA-1 on the T cell surface and ICAM-1 on APCs allows rapid T cell migration 
and differentiation (46).  
The formation of IS initiates the differentiation of naive T cells into effector T cells, 
which defend the host against various pathogens and cancer cells (46,49). Upon the 
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formation of IS, Lck phosphorylates and activates ZAP-70, a crucial protein kinase for 
the three T cell signaling pathways. The first signaling pathway is NFAT (nuclear factor 
of activated T cells), also known as the Calcium pathway. It can initiate gene expression 
by itself or with other transcription factors (52). The second pathway, NFκB (nuclear 
factor-κB), is essential for regulating immune responses and activates PKCθ, which is 
vital for T cell activation (53,54). The third pathway is Activator protein 1 (AP-1), which 
regulates gene expression, proliferation, differentiation, and even cell death (55). Though 
each pathway has its essential role, their combined effect is necessary for T cells to 
proliferate, differentiate, and have effector functions. 
2.5 Chemokine System 
 Severe tissue damage occurs when immune cells migrate to the incorrect site and 
attack healthy parts of the body. The chemokine system represents a potential target for 
immunotherapy, and it is vital to prevent tissue damage. Besides their chemotactic 
ability, chemokines can also regulate T cell development and their effector functions. The 
four subfamilies of chemokines, differentiated by their initial cysteine residues position, 
are CXC, CC, CX3C, and XC structural motifs (56,57,58). Chemokines exert their 
biological effects by binding their corresponding G protein-coupled chemokine receptors. 
Chemokines are secreted in the tumor microenvironment, and their cognate receptors are 
expressed by tumor cells. There are almost 50 distinct chemokines and 20 chemokine 
receptors identified in humans. Some chemokine receptors are specific to one chemokine, 
and others may bind to many (58). Table 1 shows chemokines (ligands) and their 
corresponding receptors (59). 
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CCR1 CCL3, CCL4, CCL5, CCL7, CCL13, CCL14, CCL15, CCL16, 
CCL23 
CCR2 CCL2, CCL7, CCL8, CCL12, CCL13, CCL16 
CCR3 CCL5, CCL7, CCL8, CCL11, CCL13, CCL15, CCL16, CCL24, 
CCL26, CCL28 
CCR4 CCL2, CCL3, CCL5, CCL7, CCL22 
CCR5 CCL3, CCL4, CCL5, CCL8, CCL11, CCL14, CCL16 
CCR6 CCL20 
CCR7 CCL19, CCL21 
CCR8 CCL1, CCL4, CCL17 
CCR9 CCL25 
CCR10 CCL27, CCL28 
CXCR1 CXCL6, CXCL8 
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CXCR2 CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8 




CXCR7 CXCL11, CXCL12 
CX3CR1 CX3CL1 
XCR1 XCL1, XCL2 
In terms of the chemokines’ function, there are two subfamilies, homeostatic and 
inflammatory chemokines. Homeostatic chemokines mainly direct the flow of leukocyte 
traffic throughout the body to screen for an invasion of pathogens. This family includes, 
but is not limited to, CCL14, CCL19, CCL20, CCL21, CCL25, CCL27, CXCL12, and 
CXCL13 (57). In different parts of the body, different chemokines recruit immune cells. 
For instance, CCL27 recruits T leukocytes in the skin, and CXCL12 mediates leukocytes 
homing in the brain (59). Some chemokines promote the formation of new blood vessels 
(angiogenesis). Although it is a part of the healing and growth of tissues, angiogenesis 
inhibitors can be essential for several diseases, including cancer. Since tumor cells need 
oxygen and nutrients to grow and spread to the other parts of the body, angiogenesis 
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inhibitors could block them from going to tumor cells. As a result, tumor cells starve and 
cannot grow or spread (60). Another chemokine family, inflammatory chemokines, is 
secreted to infection, tissue injury, or tumors. They control the inflammatory response of 
immune cells to infectious sites. CXCL8, CCL2, CCL3, CCL4, CCL5, CCL11, and 
CXCL10 are examples of inflammatory chemokines (61). However, these classifications 
are flexible, and some homeostatic chemokines may also be considered part of the 
inflammatory chemokines’ family (62).  
As one aim of this study was to have effector cells migrate to the tumor 
microenvironment directly, target and effector cells were engineered to express 
chemokines and their respective corresponding receptors. Chemokines and their 
corresponding receptors tend to bind each other. As a result, effector cells engineered to 
express chemokine receptors should be expected to go directly to the tumor 
microenvironment where the corresponding chemokines are secreted. Chemokines that 
are secreted in the tumor microenvironment depend on the type of cancer.  
2.6 Gene Therapies 
Genes maintain the production of proteins and enzymes within cells, providing 
essential body functions. Gene therapies to treat or prevent diseases have been 
investigated by scientists for decades. Gene therapy is the introduction of genomic 
material into a specific cell to give it new functions or the introduction of genomic 
material into a defective cell to correct abnormalities. There are many aspects of 




Gene therapy is divided into two categories: somatic gene therapy and germline gene 
therapy. Some consider germline therapy to be unethical as it replaces an offspring’s 
defective genes with healthier ones and is used to treat genetic disorders. It is 
controversial because it changes someone’s genetics who is not yet born, so they do not 
say whether they want treatment (63,64). Somatic gene therapy is considered to be 
ethically safer, as it affects only the patients’ genes, not future generations. There have 
been two delivery techniques for somatic gene therapy, viral and non-viral. Both delivery 
techniques have one goal: delivering genetic material across cell membranes and 
reaching the cell’s nucleus (63).  
In the 1990s, the potential of gene therapy created excitement, and many studies were 
conducted. However, the lack of experience in the clinical applications of viral vectors 
and their safety issues caused two catastrophic events. In 2003, Raper et al. reported the 
death of an 18-year-old male with partial ornithine transcarbamylase (OTC) deficiency, 
which is not a life-threatening disease. Adenovirus type 5 was used to deliver the gene 
therapy, and he was the 18th subject who received it. Before him, no one showed the 
symptoms he showed. Approximately 18 hours after the delivery, he reported not feeling 
well and died. His death was attributed to systemic inflammatory response syndrome and 
multiple organ system failures. After this experience, animal studies’ limitations in 
predicting human responses and subject-to-subject symptom variations were determined 
(65,66). Although the unsuccessful results led to a decrease in funding for gene delivery, 
there were, and still are, many scientists who believed in it. With this, gene delivery has 
become one of today’s promising therapies. 
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Viral gene delivery uses viruses to deliver genetic material; the viruses include 
adenoviruses, gamma retroviruses, lentiviruses, and adeno-associated viruses. 
Lentiviruses are a subclass of retroviruses. They have been used widely in scientific 
research as they have unique features, including the ability to integrate with both non-
dividing and dividing cells. Lentiviral vectors are derived from human immunodeficiency 
virus type 1 (HIV-1), becoming nonpathogenic and safe to use after some modifications 
(67). Naldini et al. proved that lentiviral vectors can be used in in vivo gene therapy in 
non-dividing cells, and they predicted that their feasibility in human gene therapy would 
improve (68). Lamers et al. conducted a study using gamma retroviruses instead, using γ-
retroviruses to modify the genes ex vivo of patients with metastatic renal cell carcinoma. 
In some patients, immunity against γ-retroviral vectors occurred, concerning researchers 
about γ-retroviral ex vivo applications (69). Different viral vectors have their advantages 
and disadvantages, and the selection should be specific to the study. In this study, 
lentiviruses were used to transfer the intended genetic materials to cells due to the 







3 Research Hypotheses 
3.1 Specific Aim 1: Developing a K562 Biofactory to Synthesize Therapeutic 
Proteins 
 
In this study, to find a cheaper alternative to CAR T cell therapies, K562 cells were 
explored as a biological chassis to evaluate their ability to synthesize engineered 
therapeutic proteins when engaged with ovarian cancer cells. In this part of the study, 
K562 cells were engineered with an artificial cell-signaling pathway whose design 
transforms them into antigen-specific effector cells producing Nanoluc luciferase 
enzyme, a quantifiable non-human effector protein. This pathway contained three 
constants (receptor, actuator, secretor) and two variable (sensor, effector) domains. 
Whereas the constant domains gave biofactory functionality, the variable domains 
expanded the possibility of targeting different cell-based diseases. 
The artificial cell signaling pathway developed here was a third-generation CAR. It 
was developed to be activated by an immunological synapse, which was to be formed 
between K562 cells and ovarian cancer cells when they engage with one another. When 
the pathway was activated, it was expected K562 cells synthesize the Nanoluc luciferase 
enzyme. In order to have quantifiable results and demonstrate if this system has worked, 
a NanoGlo luciferase assay system was used to measure the production of Nanoluc 
luciferase reporter. The null hypothesis was that K562 can be used as a cellular chassis 
for developing a biofactory technology as an alternative to T cells in the treatment of 
ovarian cancer, and the alternate hypothesis was the other way around. 
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3.2 Specific Aim 2: Engineering Jurkat Cells with Chemokine Receptors to Evaluate 
Their Migration Towards the Ovarian Cancer Microenvironment and Their 
Cytotoxic Functions on Tumor Cells 
 
In the second part of the study, the aim was to prevent tissue damage on healthy areas 
of the body and to see the cytotoxic functions of Jurkat cells on tumor cells. In order to 
have Jurkat cells migrate directly towards the tumor microenvironment, they were 
engineered to express two chemokine receptors independently. When chemokine 
receptors interact with chemokines, they tend to bind to corresponding ligands.  For this 
study, appropriate chemokine receptors were expected to be highly expressed on 
cytotoxic T cells (CD8+ T cells) and helper T cells (CD4+ T cells). Also, their low 
expression on T regulatory cells was another consideration. The reason was that Treg 
cells, also known as suppressor T cells, regulate and suppress other immune cells’ 
functions. So, their activation could prevent the migration of cytotoxic T cells into the 
tumor microenvironment. The chemokine receptors selected here were CCR5 and CCR7 
due to the reasons mentioned above. Whereas Jurkat cells were engineered to express 
CCR5 and CCR7, ovarian cancer cells were engineered to express CCL5 and CCL19, the 
corresponding ligands of CCR5 and CCR7. As a result, it was expected that CCR5 and 
CCR7 chemokine receptors of Jurkat cells would migrate directly towards the 
corresponding ligands and bind to them. 
On the other hand, to give cytotoxic functions to Jurkat cells, they were modified to 
express CAR on their cell surface. Jurkat cells were also modified with anti-folate 
receptor alpha to recognize folate receptor alpha, a receptor highly expressed on ovarian 
cancer cells’ surface. The last modification done was the engineering of Jurkat cells with 
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luciferase enzyme to give them quantifiable features. Here again, a NanoGlo luciferase 




4 Materials and Methods 
In this part, the materials and methods used to test the hypotheses for the two specific 
aims are discussed.  
4.1 Specific Aim 1 
To test the hypothesis of the specific aim 1, Jurkat and K562 biofactories were 
developed by designing an artificial cell-signaling pathway. As mentioned earlier, this 
pathway included five domains: the receptor, the actuator, the secretor, the sensor, and 
the effector. The receptor part was generated by adding an activator motif, CD3ζ, and co-
stimulatory molecules, 4-1BB and CD28. The CAR generated here was the third 
generation. Whereas CD3ζ led to a rise in the intracellular calcium (Ca2+) concentration, 
the combination of 4-1BB and CD28 enhanced the therapeutic response of CAR T cells. 
The actuator part was based on six copies of NFAT-RE (NFAT-RE6X, nuclear factor of 
activated T cell response) that would respond to Ca2+ rise and upregulate luciferase 
activity. The secretor part was composed of human interferon alpha-2 (IFN-2) that 
activates T cells to fight cancer cells and inhibits tumor cells’ proliferation. The other two 
parts, the sensor, and the effector, were subject to change depending on the study. In this 
case, the sensor part was developed to detect folate receptor alpha (FR), which is a 
receptor found on the surface of many cancer cells including ovarian cancer cells. Two 
different ovarian cancer cell lines (OVCAR-3 and A2780cis) were used in this study. 
OVCAR-3 human ovarian cancer cells were used as target cells because they express 
FR and can be detected by the anti-folate receptor alpha on the biofactory cells’ surface. 
On the other hand, A2780cis human ovarian cancer cells lacking FR were used as non-
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target negative controls. The fifth part of the pathway, an effector part, may comprise 
different reporter transgenes. In this study, a quantifiable non-human effector protein, 
Nanoluc luciferase reporter, was used for proof-of-concept. If biofactories can produce 
Nanoluc enzyme, they can be manipulated with different therapeutic proteins, instead of a 
quantifiable non-human protein, to give them therapeutic functions.  
To generate Jurkat and K562 biofactories, lentiviruses, with the necessary genetic 
material mentioned earlier, were produced by the transfection of HEK293T/17 cells. 
Once lentiviruses were generated, Jurkat and K562 parental cell lines were transduced 
with these viruses. To check if the transduction was successful, engineered cells' 
live/dead status was compared to one of the positive control cells (parental cell lines). 
Both transduced and unmodified cells were placed under selection for two weeks with 
puromycin, a type of antibiotic used to select and maintain cells stably transfected with 
viral vectors expressing puromycin. It was expected that successfully engineered cells 
stay alive under the selection. Once alive engineered cells were selected and grown in the 
laboratory, they were co-cultured with target and non-target cancer cells. The Nanoluc 
activity of cell biofactories was measured with a microplate reader called NanoGlo 
Assay. Three 96-well plates were seeded with different co-culture combinations to 
measure the Nanoluc activity produced by Jurkat and K562 biofactories when they 
engaged the target and non-target cells in respect to 24hr, 48hr, and 72hr. Figure 1 




Jurkat Biofactory and OVCAR-3  
Jurkat Biofactory and A2780cis 
K562 Biofactory and OVCAR-3 
K562 Biofactory and A2780cis 
Jurkat Biofactory cells 
K562 Biofactory cells  
OVCAR-3 cells  
A2780cis cells  
 
Figure 1. The combination of seeded cells in the 96-well plates 
To understand the effect of cancer cells’ mass on the Nanoluc synthesis, another 
NanoGlo assay was applied with the cell combinations shown in Figure 1. In this 
experiment, effector cell numbers remained constant, and target cell numbers were 
serially diluted. Nanoluc activity of biofactories was measured at 24 hours of co-culture.  
4.1.1 Materials and Reagents  
K562-BF, Jurkat-BF, OVCAR-3 (ATCC), and A2780cis (ATCC) cell lines were 
maintained in complete RPMI media [RPMI1640 with L-glutamine (Corning, CAT#    
10-040CV), and 10% fetal bovine serum (Sigma-Aldrich, Cat# F2442-500ml)]. 
Puromycin dihydrochloride (Thermo Fisher Scientific, Cat# A1113803) was used for 
selecting engineered cells.  
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4.1.2 Reviving Cell Lines 
Already engineered K562-BF and Jurkat-BF cell lines were provided by Dr. Parijat 
Bhatnagar’s laboratory. All frozen cells were rapidly (< 2 minute) thawed in a 37°C 
water bath. Thawed cells were slowly diluted with 10ml of pre-warmth complete RPMI 
media in a Falcon 15 mL conical centrifuge tube. Then, 15 mL tube was vortexed and 
centrifuged at 200G for 8 minutes. After the supernatant was removed, cells were 
resuspended with 5ml of growth media. After 48 hours of revival, K562-BF and Jurkat-
BF were placed in selection using 0.5 µg mL-1 and 0.2 µg mL-1 of puromycin 
dihydrochloride respectively for two weeks. After selection, all cell line were expanded 
for NanoGlo Assays and then were frozen using freezing media (complete culture media 
and 10% DMSO) for liquid nitrogen stocks.  
4.1.3 Stimulation of Biofactories  
2500 cells of OVCAR-3 and A2780cis were co-cultured with 12500 cells of Jurkat-
BF and K562-BF in 100 µL of complete RPMI media in a single well of 96-well plate. 
Also, OVCAR-3, A2780cis, Jurkat-BF and K562-BF were also seeded as controls, which 
were to be chemically stimulated with PMA ionomycin to evaluate the function of 
biofactories. Three 96-well plate were seeded for three time points (24, 48, and 72 hours).  
4.1.4 Stimulation of Biofactories with Variant Target Cells’ Mass 
  12500 cells of Jurkat-BF and K562-BF were co-cultured with variant target and non-
target cell numbers (from 125000 to 976) in 100 µL of complete RPMI media in a 96-




4.1.5 NanoGlo Assay to Measure Nanoluc Activity 
 Nanoluc substrate was diluted in the cell lysis buffer, which was provided with the 
NanoGlo assay. It was added 1:1 to cells. After 3 minutes of incubation, Nanoluc activity 
of biofactory cells was read on a microplate reader (Perkin Elmer, Envision Multilabel 
Plate Reader Model: 2104-0010A).  
4.2 Specific Aim 2 
In this part of the study, the aim was to have effector cells, Jurkat cells, migrate 
towards the ovarian cancer cells, OVCAR-3 cells. Jurkat parental cells were manipulated 
with lentiviruses to recognize FR on OVCAR-3 cells’ surface. Also, they were 
engineered, independently, to express CCR5 and CCR7 chemokine receptors, and not to 
express CCR5 and CCR7. The cells engineered with CCR5 and CCR7 expressed these 
chemokine receptors on their cell surfaces. On the other hand, the cells engineered with 
CCR5 endogenous shRNA and CCR7 endogenous shRNA did not express these 
receptors. shRNA molecules knocked down gene expression. To check their chemotactic 
ability Jurkat cells were co-cultured with OVCAR-3 cells (target cells), which were 
engineered to express CCL5+, CCL5-, CCL19+, and CCL19-, the corresponding ligands of 
CCR5+, CCR5-, CCR7+, and CCR7-. Figure 2 illustrates different combinations of 
chemokine receptors expressed by Jurkat cells and chemokines secreted in the ovarian 





CCR5- and CCL5- 
CCR5+ and CCL5- 
CCR5- and CCL5+ 
CCR5+ and CCL5+ 
CCR7- and CCL19- 
CCR7+ and CCL19- 
CCR7- and CCL19+ 
CCR7+ and CCL19+ 
 
Figure 2. Combinations of chemokines and their receptors 
 
4.2.1 Materials and Reagents 
 Parental Jurkat and OVCAR-3 cells (ATCC) were maintained in complete RPMI 
media [RPMI1640 with L-glutamine (Corning, CAT# 10-040CV), and 10% fetal bovine 
serum (Sigma-Aldrich, Cat# F2442-500ml)] to be engineered. HEK293T/17 cells were 
maintained in complete DMEM media [DMEM with L-glutamine and 10% fetal bovine 
serum) to produce lentiviruses. Puromycin dihydrochloride (Thermo Fisher Scientific, 




4.2.2 Lentivirus Production 
  HEK293T/17 cells were seeded and maintained in complete DMEM. In a 1.5mL 
microtube, 150mM NaCl, pAdv, pMD2.G, psPAX2, transporter, and the corresponding 
transfer plasmid [LentiStarter 2.0 kit (System Biosciences)] were mixed. This mixture 
was added on the plated HEK293T/17. Viral supernatant was collected 24, 48, and 72 
hours after transfection. Viral supernatant was filtered and ultracentrifuged by using 
Polypropylene Konical ultracentrifugation tube (Beckman Coulter #C14291) in Beckman 
Coulter ultracentrifuge (Beckman Coulter #369650). 
4.2.3 Transduction of Parental Cell Lines 
 Corresponding lentivirus particles were added to parental cell lines (Jurkat and  
OVCAR-3). After five hours of incubation, polybrene was added to flasks.  
4.2.4 Boyden Chamber Assay 
 Respective OVCAR-3 cells engineered with ligands were seeded at 10000 per well 
in a 24-well plate. After 24 hours of incubation, respective Jurkat cells engineered with 
chemokine receptors were seeded at 1x106 per well in Boyden chambers. Boyden 
chamber assemblies were incubated for 3 and 6 hours, and Boyden chambers were 
discarded. Migrated Jurkat cells were allowed to be co-cultured with OVCAR-3 cells for 
48 hours. 
4.2.5 NanoGlo Assay to Measure Luciferase Activity 
Luciferase reagent was added to each well of 24-well plate and plates were incubated 
for 5 minutes. Cells in 24-well plate were transferred to 96-well plate to be read 
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luminescence on a microplate reader (Perkin Elmer, Envision Multilabel Plate Reader 
Model: 2104-0010A). 
The most important safety consideration for Specific Aim 1 and 2 was to work with 
lentiviral vectors. While working with viruses, double gloves, double lab coats, and lab 
goggles must be worn. Also, ten percent of bleach must be always found in the hood to 


















In this thesis, two hypotheses were evaluated to be true or false through the data 
obtained by various experiments explained above. The first hypothesis was that K562 
cells could be used as a cellular chassis for developing a biofactory technology to 
produce therapeutic proteins for targeting diseased cells. In the first part (Figure 3, Figure 
4, Figure 5), the hypothesis that K562 cells synthesize engineered proteins in situ upon 
the interaction with ovarian cancer cells was evaluated. In the second part of the study 
(Figure 6, Figure 7), the hypothesis that manipulated Jurkat cells migrate towards ovarian 
cancer cells and have a cytotoxic effect on them was evaluated. For all comparisons of 
statistical significance, two-sample t-tests with common variance were used. Values of P 
< 0.05, P < 0.01, and P < 0.001 were considered as being significant, very significant, and 
extremely significant respectively. Values of P > 0.05 were considered as being not 
significant. The results are expressed as mean (M) ± standard deviation (SD). 
5.1 Specific Aim 1. K562 Biofactory Function 
5.1.1 NanoLuc Luciferase Expression Measurement of Chemically Stimulated 
Biofactories 
 
First, the function of K562 and Jurkat cell biofactories that had been chemically 
stimulated with Phorbol 12-Myristate 13-Acetate (PMA) ionomycin formulation were 
tested to see whether the cells were engineered successfully, and they were able to 
synthesize the NanoLuc enzyme. The comparison between chemically stimulated and 




Figure 3. Demonstration of chemically stimulated K562 and Jurkat cells biofactories’ 
function. Chemically stimulated and non-stimulated effector cells from both biofactories 
were compared to each other. 50,000 cells were seeded for each condition. Statistics 
between K562 and Jurkat biofactories were calculated by a two-sample t-test assuming 
equal variances. Values are expressed as mean ± SD. P values: *P < 0.05, **P < 0.01, 
***P < 0.001. a.u., arbitrary unit. 
Nanoluc activity of chemically stimulated and non-stimulated Jurkat biofactories 
(Jurkat-BF) was measured as 82 x 106 a.u. ± 1.4 x 106 and 2.4 x 106 a.u. ± 0.11 x 106; 
Nanoluc activity of chemically stimulated and non-stimulated K562 biofactories (K562-
BF) was measured as 57.4 x 106 a.u. ± 4.7 x 106 and 0.421 x 106 a.u. ± 0.064 x 106. 
Statistical analysis supported that the difference between the amount of Nanoluc 
synthesized by chemically stimulated and non-stimulated biofactories was extremely 


















































chemically stimulated biofactories were able to produce a significant amount of Nanoluc 
compared to a non-stimulated biofactory. 
5.1.2 NanoLuc Luciferase Expression Measurement of Biofactories that Interact with 
Cancer Cells 
 
Second, to evaluate the K562 biofactory function in situ upon interaction with ovarian 
cancer cells, Nanoluc expression of effector cells (K562-BF and Jurkat-BF) and target 
cells (OVCAR-3 and A2780cis cells) co-cultures were measured and compared to each 
other. Co-culture of effector cells with OVCAR-3 cells were used as positive controls, 
and co-culture of effector cells with A2780cis cells were used as negative controls.  
It was expected that both biofactories would produce the Nanoluc enzyme when 
engaged with OVCAR-3 cells. The Nanoluc amount expressed by K562-BF was 
compared to the one expressed by Jurkat-BF to evaluate whether K562 cells could be 
substituted for T cells as a cellular chassis for developing a biofactory technology. 
The chemically stimulated biofactories were able to synthesize the Nanoluc enzyme 
whereas chemically stimulated target cells were not (Figure 3). When the Nanoluc 
expression of the positive control and negative control of Jurkat-BF (13.43 x 106 a.u. ± 
1.3 x 106 and 0.95 x 106 a.u. ± 0.13 x 106) were compared to each other, it was seen that 
Jurkat cells synthesize Nanoluc in situ upon interaction with OVCAR-3 cells. This 
finding was also supported by a two-tail t-test (p = 0.008). It was concluded that the 
difference between co-cultures of Jurkat-BF with positive and negative controls was very 
significant. However, the co-cultures of K562-BF with OVCAR-3 and A2780cis (0.21 x 
106 a.u. ± 0.014 x 106 and 0.17 x 106 a.u. ± 0.035 x 106) expressed almost the same 
amount of Nanoluc enzyme (p = 0.46), meaning K562-BF did not produce Nanoluc when 
36 
 
engaged with antigen-presenting target cells. To confirm this finding, a two-tailed t-test 
between co-cultures of biofactories with OVCAR-3 was applied and again K562-BF did 
not produce Nanoluc enzyme as Jurkat-BF did (p = 0.007, a very significant difference). 
All t-tests were done according to the data at 48 hours (Figure 4).   
 
Figure 4. Nanoluc expression measurement of effector cells, JURKAT-BF and K562-BF, 
after co-culture with target cells, OVCAR-3 and A2780cis, and of chemically stimulated 
(PMA ionomycin) K562-BF, JURKAT-BF, OVCAR-3, and A2780cis cells at 24, 48, and 
72 hours. 12,500 effector and 2,500 target cells were seeded for each condition. Statistics 
were calculated by a two-sample t-test assuming equal variances. Values are expressed as 








































































5.1.3 Effect of Target Cells’ Mass on Nanoluc Enzyme Expression 
Last, we tested the effect of target cells’ mass (OVCAR-3 and A2780cis) on Nanoluc 
enzyme synthesis by the biofactories. Eight different amount of target cells (from 
125,000 to 976 cells) were co-cultured with same amount of effector cells. For Jurkat-BF, 
effector protein activity was proportional to the mass of target cells. However, for K562-
BF, the mass of target cells did not have any effect on the Nanoluc expression as K562-
BF cells were almost unable to produce Nanoluc enzyme when encountered by the 
antigen presenting target cells (Figure 5). This finding was supported by statistical 
analysis done between the co-cultures of biofactories with OVCAR-3 cells, where the 
number of seeded cells of effector and target cells were 12,500 and 125,000 respectively. 
It was concluded that K562-BF did not produce Nanoluc as Jurkat-BF did, and there was 
an extremely significant difference between their Nanoluc expression 
(p = 2.9 x 10-6). 
 
Figure 5. Evaluation of the effect of target cells’ mass on the effector cells’ Nanoluc 
expression. Target cell numbers were serially diluted from 125,000 to 976 cells whereas 
effector cell numbers remained constant at 12,500 cells. Statistics were calculated by a 
two-sample t-test assuming equal variances. Values are expressed as mean ± SD. P 
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5.2 Specific Aim 2. Function of CAR Jurkat Cells Engineered with Chemokine 
Receptors 
 
In this part of the study, the migration and cytotoxic ability of Jurkat cells on 
OVCAR-3 cells were tested. Results were found by measuring luciferase (Luc2) 
expression of cancer cells. 
5.2.1 Function of CCR5 Jurkat Cells  
First, we tested the killing ability of Fr-CAR Jurkat cells expressing CCR5 on 
OVCAR-3 cells. Various statistical analyses were applied with different co-cultures 
combinations illustrated in Figure 2. Fr-CAR Jurkat cells expressing CCR5 chemokine 
receptor (Jurkat CCR5+) were co-cultured with OVCAR-3 expressing CCL5 (OVCAR-3 
CCL5+) and OVCAR-3 non-expressing CCL5 (OVCAR-3 CCL5-). Fr-CAR Jurkat non-
expressing CCR5 (Jurkat CCR5-) was also co-cultured with OVCAR-3 CCL5+. Then, the 
migration and cytotoxic ability of Fr-CAR Jurkat cells on OVCAR-3 cells were 
measured at 3 and 6 hours. Luc2 expression of OVCAR-3 cells are illustrated below 




Figure 6. The migration ability and cytotoxic effect of CAR Jurkat CCR5+ and CAR 
Jurkat CCR5- on OVCAR-3 CCL5+ and OVCAR-3 CCL5- are shown by the 
measurement of Luc2 expression of target cells. Luc2 expression of OVCAR-3 CCL5- 
cells co-cultured with CAR Jurkat CCR5+ and CAR Jurkat CCR5- were measured as 
12356 a.u. and 9329 a.u. at 3 hours, and 20516 a.u. and 14849 a.u at 6 hours respectively. 
Luc2 expression of OVCAR-3 CCL5+ cells co-cultured with CAR Jurkat CCR5+ was 
measured as 2604 a.u. at 3 hours and 2498 a.u. at 6 hours. OVCAR-3 cells and CAR 
Jurkat cells were seeded at 10,000 and 1x106 cells for each condition. Statistics were 
calculated by a two-sample t-test assuming equal variances. Values are expressed as 
mean ± SD. P values: *P < 0.05, **P < 0.01, ***P < 0.001. a.u., arbitrary unit. 
It was hypothesized that Jurkat CCR5+ cells would migrate more towards OVCAR-3 
CCL5+ cells and have a higher cytotoxic effect on them compared to their co-culture with 
OVCAR-3 CCL5- cells after both 3 and 6 hours. This hypothesis was proven by 













































OVCAR-3 CCL5+ at 3 and 6 hours (p = 0.027 at 3 hours and p = 6x10-5 at 6 hours). 
Another analysis was done between 3 and 6 hours to understand whether time has an 
effect on the migration and killing ability of Jurkat cells. It was found that the cytolytic 
ability of Jurkat CCR5+ cells on OVCAR-3 CCL5+ cells remained constant after 3 and 6 
hours co-culture (p = 0.79, no significant difference).  
The second hypothesis was that Fr-CAR Jurkat CCR5+ cells would migrate more 
towards OVCAR-3 CCL5+ cells and have more killing effect on them than the migration 
and killing ability of Jurkat CCR5- cells on OVCAR-3 CCL5- cells. This hypothesis was 
supported by the statistical analysis done between Jurkat CCR5+ / OVCAR-3 CCL5+ and 
Jurkat CCR5- / OVCAR-3 CCL5- at both 3 and 6 hours. At 3 hours the difference was 
very significant (p = 0.0034) and at 6 hours the difference was extremely significant       
(p = 6x10-7).  
5.2.2 Function of Jurkat Cells Expressing CCR7+ and CCR7- 
Second, we tested the migration and killing ability of Fr-CAR Jurkat cells 
expressing CCR7 on OVCAR-3 cells. The hypothesis for this stage of the study remained 
the same as the previous stage, which Fr-CAR Jurkat CCR7+ cells would migrate more 
towards OVCAR-3 CCL19+ cells and would have a higher cytotoxic effect on them 
compared to their co-culture with OVCAR-3 CCL19- cells. Luc2 expression of   





Figure 7. The migration ability and cytotoxic effect of CAR Jurkat CCR7+ and CAR 
Jurkat CCR7- on OVCAR-3 CCL19+ and OVCAR-3 CCL19- are shown by the 
measurement of Luc2 expression of target cells. Luc2 expression of OVCAR-3 CCL19- 
cells co-cultured with CAR Jurkat CCR7+ and CAR Jurkat CCR7- were measured as 
26871 a.u. and 16267 a.u. at 3 hours, and 32467 a.u. and 16293 a.u. at 6 hours 
respectively. Luc2 expression of OVCAR-3 CCL19+ cells co-cultured with CAR Jurkat 
CCR7+ was measured as 4627 a.u. at 3 hours and 3760 a.u. at 6 hours. OVCAR-3 cells 
and CAR Jurkat cells were seeded at 10,000 and 1x106 cells for each condition. Statistics 
were calculated by two-sample t-test assuming equal variances. Values are expressed as 
mean ± SD. P values: *P < 0.05, **P < 0.01, ***P < 0.001. a.u., arbitrary unit. 
The Fr-CAR Jurkat CCR7+ cells migrated more to OVCAR-3 CCL19+ than 
OVCAR-3 CCL19- at both 3 and 6 hours. The difference at both 3 and 6 hours was 
extremely significant (p = 0.00014 and p = 3.8x10-5). The cells’ killing ability at 3 and 6 

















































CCR7+ cells’ killing ability on OVCAR-3 CCL19+ was much higher than Jurkat CCR7- 
cells on OVCAR-3 CCL19-. The difference between their cytolytic effect at 3 and 6 





Despite having unprecedented and unparalleled results in cancer treatments, CAR T 
cell therapies are not affordable for many patients and may have fatal side effects. Thus, 
Bhatnagar et al. studied T cell biofactory technology (45) and transformed T cells into 
living vectors to synthesize therapeutic proteins in situ when engaging with diseased cells 
in the body. Yet, this technology is very expensive and may have side effects as it uses 
Jurkat cells, an immortalized line of human T lymphocytes cells. This thesis aimed to 
create a cheaper and safer alternative to CAR T cell therapy by testing the hypothesis that 
K562 cells can be used as a cellular chassis to synthesize therapeutic proteins when 
encountering diseased cells. K562 cells used in this research were derived from a 53-
year-old woman with chronic myelogenous leukemia in blastic crisis, and they can be 
easily manipulated and keep the expression of manipulated genes stable (70).  
To evaluate the hypothesis, this study was divided into two parts. The first part 
investigated whether K562 cells would synthesize the engineered protein, Nanoluc 
luciferase, when interacting with antigen-presenting cells. The second part evaluated 
whether engineered Jurkat cells migrate to target cells with the help of chemokine 
receptors and if they have a cytolytic effect on them. If promising results from the second 
part were found, the same system could be implemented in K562 biofactories in later 
studies. 
6.1 K562 Biofactory Function Evaluation 
A brief ex-vivo stimulation of Jurkat and K562 biofactories was conducted using 
PMA ionomycin. PMA ionomycin formulation activates multiple intracellular signaling 
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pathways, resulting in the biofactories’ activation. While there are other methods to 
stimulate cytokine production, the optimal method is to use this formulation, as found by 
Ai et al. in 2013 (71). 
PMA activates protein kinase C (PKC), which has an essential role in mature T cell 
activation. When immune cells are engaged with antigens of cancer cells in normal 
conditions, CD3ζ, a part of CAR signaling, causes Ca2+ to rise within the cells. PKC 
enzymes are in turn activated by these signals. Consequently, T cells are activated. 
Alternately, ionomycin is a calcium ionophore that facilitates the calcium ion transfer 
into and out of cells. When ionomycin is combined with PMA, they activate NFκB and 
NFAT transcription factors, leading to cytokine production (72).  
As previously mentioned in Materials and Methods for Specific Aim 1, the artificial 
cell-signaling pathway of both biofactories was composed of three constant domains 
(receptor, actuator, secretor) and two variable domains (sensor, effector). The receptor 
domain consisted of the CD3ζ signaling domain (causing Ca2+ to increase upon 
interaction with antigen-presenting cells), the CD28 that connects the intracellular and 
extracellular domains of CAR, and 4-1BB that enhances the therapeutic response of 
CAR. The actuator domain contained six copies of NFAT-RE (NFAT-RE6X), and IFN 
alpha-2 was selected as a secretor due to its high Nanoluc activity. Bhatnagar et al. 
evaluated three versions of the actuator domain (three, six, and nine copies of NFAT-
RE), and five different signal peptides for the secretor domain (HSA, IL-6, IL-2, Gluc, 
and IFN alpha-2) (45). Specific to this study, the sensor part was derived from an anti-
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Fr antibody to detect Fr receptor on target cells. The Nanoluc reporter enzyme was 
used as an effector.  
As both biofactories were engineered with identical constant and variable domains, 
their structure was expected to be the same. Thus, it was anticipated that PMA ionomycin 
would activate them both. From the comparison of the Nanoluc expression by chemically 
stimulated and non-stimulated biofactories, it was concluded that biofactories activated 
by PMA ionomycin were able to synthesize Nanoluc whereas non-stimulated ones were 
not (Figure 3). This meant the engineering of K562 and Jurkat cells was successful, and 
the cells were ready to be co-cultured with antigen-presenting target cells and non-target 
cells to evaluate their function of Nanoluc synthesis in situ upon engaging with cancer 
cells.  
The feasibility of the K562 cell biofactory’s engineered protein synthesis for targeting 
diseased cells was compared to the Jurkat biofactory, the feasibility of which was already 
proven in situ upon engaging with ovarian cancer cells (45). Both biofactories were 
engineered to recognize a specific receptor on the cancer cells’ surface, facilitating their 
protein expression after stimulation.  
Two different ovarian cancer cell lines were used to prove the function of 
biofactories. The rationale behind the selection of two distinct ovarian cancer cell lines 
was the expression of a specific receptor, Fr. Fr is overexpressed on OVCAR-3 cells, 
and its expression on normal cells is limited (45, 73). Thus, OVCAR-3 cells were used as 
target cells (positive controls) as Fr would enable ligand-receptor recognition between 
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cancer cells and biofactories. A2780cis cells lacking Fr were used as non-target 
negative controls.  
Upon engaging target cells and biofactories, it was expected that Fr on Jurkat-BF 
and K562-BF would engage the antigens on target diseased cells, which would, in turn, 
result in biofactory activation. Along with this activation, Nanoluc and IFN-2 syntheses 
were upregulated. IFN-2 (secretor peptide) was cleaved off, and Nanoluc (effector 
peptide) was transported in the extracellular space (45).  
The results obtained from the co-culture of Jurkat-BF, with positive and negative 
controls, demonstrated that Fr found on the surface of OVCAR-3 cells enabled Jurkat-
BF’s stimulation and thus synthesized the Nanoluc reporter enzyme. Nanoluc enzyme, 
which produces bright and sustained luminescence (74), represented a quantifiable non-
human effector protein. The Nanoluc expressed by Jurkat-BF co-cultured with OVCAR-3 
cells was much greater than the Jurkat-BF and A2780cis co-culture at 24, 48, and 72 
hours (Figure 4). The findings of Bhatnagar et al. (45), a similar study, support these 
results. 
Even though both Jurkat and K562 cells were engineered with the same artificial cell-
signaling pathway, co-cultured K562-BF and OVCAR-3 did not elicit similar results to 
the co-cultured Jurkat-BF and OVCAR-3. The results of the chemically stimulated K562 
cells’ expression of the Nanoluc enzyme showed that they were successfully stimulated 
by PMA ionomycin and synthesized the Nanoluc enzyme. However, when they were 
engaged with antigen-presenting target cells, the pathway was not activated, and K562 
cells were not able to produce the Nanoluc enzyme. In other words, when PMA, a PKC 
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activator, was not added to the culture media, the engagement of K562 and target 
antigens was not sufficient to activate the cell signaling pathway. As such, the PKC 
enzymes were not activated by the insufficient initial Ca2+rise, which would have driven 
the NFAT signaling pathway activity, in turn upregulating Nanoluc activity (45, 75).  
These results should be taken into account when considering how other cells line can 
be substituted with T cells for immunotherapies. Since the constant domains of the 
signaling pathway of this study give the biofactory functionality, it is highly possible that 
at least one of the constant domains did not perform its function. As a result, the 
immunological synapse was not formed between K562 cells and target cells. An 
immunological synapse is an interface between antigen-presenting cells and lymphocytes 
such as T cells. For the integration of an immunological synapse, there are three broad 
categories of receptors: antigens, adhesion molecules, and costimulatory molecules, 
which are involved in T cell activation (46). Since Jurkat cells have all the machinery that 
Primary T cells have, the immunological synapse between Jurkat-BF and OVCAR-3 cells 
successfully formed. However, K562 cells do not express all the receptors that Jurkat 
cells do. As a result, it was concluded that K562-BF was not a good choice to be 
substituted with Primary T cells to recreate biofactory technology. 
The ICAM-1 and LFA-3 adhesion molecules that are required to form an effective 
immunological synapse are expressed by K562 cells. However, K562 cells do lack many 
molecules that are necessary for the formation of the immunological synapse and the 
activation of biofactories. The co-stimulatory signal, the second signal to activate an 
immune response when engaged with antigen-presenting cells, depends on two co-
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stimulatory molecules expressed by T cells. One of them is CD28, which was expressed 
by K562-BF as it was used to manipulate both biofactories. However, ICOS (Inducible 
co-stimulator or CD278), the second co-stimulatory molecule for T cell proliferation and 
cytokine secretion, was not expressed by K562 cells (46, 70).  
Furthermore, K562 cells do not express the T cell receptors that enable T cells to 
form the complex with CD3, the interaction of which would trigger an antigen-specific 
immune response. Upon the formation of an immunological synapse, Lck (lymphocyte-
specific protein tyrosine kinase) phosphorylates and activates ZAP-70, a protein whose 
activation is required for the induction of NFAT transcriptional activity (76). All these 
molecules have a specific function in the formation of an immunological synapse and, in 
consequence, the synthesis of therapeutic proteins. It is highly possible that the lack of 
these molecules is the reason that K562-BF did not synthesize the Nanoluc enzyme when 
engaging with target cells. 
6.2 Function of Jurkat Cells that are Engineered to Express Chemokine Receptors  
Chemokines are vital for many biological activities. The chemokine system 
represents a potential target for immunotherapy, and it is vital in preventing healthy tissue 
damage in the body. Chemokines, a large family of cytokines, control the migration and 
positioning of immune cells within the body. In this part of the study, we generated a 
second-generation Fr specific chimeric antigen receptor. The antigen recognition motif 
was composed of an anti-folate receptor alpha antibody. The signaling domains consisted 
of CD28 and CD3ζ.  
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Jurkat cells were engineered to express this CAR receptor along with the CCR5 and 
CCR7 chemokine receptors, in order to evaluate their migration and cytolytic ability on 
cancer cells. Whereas the CAR receptor gave Jurkat cells the killing ability, the anti-Fr 
antibody enabled them to recognize human ovarian cancer antigen, folate receptor alpha, 
on OVCAR-3 cells. The rationale behind the selection of CCR5 and CCR7 chemokine 
receptors was that CCL5 and CCL19, corresponding ligands of CCR5 and CCR7, are 
highly produced in the ovarian tumor environment (77, 78, 79). As a proof of concept, 
OVCAR-3 cells were also engineered to express CCL5 and CCL19 as their receptors 
enable Jurkat cells to migrate and bind to their corresponding ligands. Target cells were 
also engineered to express luciferase (luc2), which was measured to see whether 
OVCAR-3 cells were alive. Since luciferase activity is ATP-dependent, dead cells cannot 
produce bioluminescence. If the amount of luc2 were too high, it means OVCAR-3 cells 
are alive and able to produce luc2 enzyme. 
Figure 6 and Figure 7 show the luc2 expression of OVCAR-3 cells that were co-
cultured with Jurkat cells, expressing CCR5 and CCR7. The results and analysis 
supported the theory that Jurkat CCR5+ and Fr-CAR Jurkat CCR7+ cells migrated 
successfully towards OVCAR-3 CCL5+ and OVCAR-3 CCL19+ cells at 3 and 6 hours. 
Both cells were found to be responsive to their corresponding ligands. Aldinucci et al. 
(2020) and Cheng et al. (2020) supported the idea that CCR5/CCL5 and CCR7/CCL19 
could be targeted in ovarian cancer (80,81). Both Jurkat cells, which express CCR5 and 
CCR7, had the same cytolytic ability on target cells at different hours (3 and 6 hours). It 




Options for low-cost manufacturing and safer cell therapies were evaluated 
throughout this research. To find a safer and cheaper alternative to CAR T cell therapies, 
K562 cells were explored whether to be used instead of T cells. The rationale behind 
using this cell line is that it has been approved as safe to be reinfused into the human 
body by the FDA. Also, it is cheaper compared to T cells. Therefore, therapies generated 
by K562 cells may be more affordable and safer for cancer patients.   
Even though K562 cells were engineered with the same biofactory as Jurkat cells, 
they were not able to synthesize Nanoluc protein as Jurkat cells did. Jurkat cells, an 
immortalized line of T cells, have all the machinery that T lymphocytes have. As a result, 
when they encounter antigen-presenting cells, an immunological synapse forms and 
activates the biofactory. Upon activation of the biofactory, Jurkat cells synthesize 
engineered proteins. K562 cells lack some of the molecules and receptors vital for the 
formation of an immunological synapse. Thus, in situ upon interacting with antigen-
presenting cells, intracellular signaling pathways were not activated. Therefore, the 
signaling pathways whose activation is necessary to produce therapeutic proteins were 
not activated either.  
The study's second aim was to have effector cells migrated directly towards target 
cells without harming the healthy sides of the body by using the chemokine system. 
Effector cells and target cells were engineered to express chemokines and chemokine 
receptors respectively to bind one another. This part of the study showed that the 
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Appendix A Specific Aim 1. K562 Biofactory Function 
Table 2 shows NanoLuc expression amounts of chemically stimulated biofactories. 
 
Table 2. Means and Standard Deviation of Nanoluc Expression Measurements of Jurkat 
and K562 Biofactories 
Effector 
Cells 
Mean (x106 a.u.) Standard Deviation (x106 a.u.) 
PMA/Io No treatment PMA/Io No treatment 
Jurkat BF 82 2.4 1.4 0.11 
K562 BF 57.4 0.421 4.7 0.064 
 
Table 3 shows NanoLuc expression amounts of biofactories that interact with cancer 
cells. 
 
Table 3. Means and Standard Deviation of Nanoluc Expression Measurements of Effector 




Mean (x106 a.u.) 
 
Standard Deviation (x106 a.u.) 
24 hrs 48 hrs 72 hrs 24 hrs 48 hrs 72 hrs 
JK-BF / OVCAR-3 12 13.43 18.1 1.4 1.3 0.6 
JK-BF / A2780cis 0.9 0.95 1.5 0.12 0.13 0.047 
K562-BF / OVCAR-3 0.13 0.21 0.27 0.0092 0.014 0.13 
K562-BF / A2780cis 0.16 0.17 0.1 0.03 0.035 0.031 
JK-BF 2.1 4.5 7.1 0.4 1.4 1.04 
OVCAR-3 0.21 0.21 0.021 0.003 0.004 0.006 
K562-BF 7.1 7.8 7.6 0.19 0.21 0.29 










Table 4 introduces the Nanoluc enzyme expressions of the biofactories that were co-
cultured with positive and negative controls. 
Table 4. Nanoluc Expression Amounts After 24 hours of Co-culture of Target and 




























































































Appendix B Specific Aim 2. Function of CAR Jurkat Cells Engineered with 
Chemokine Receptors 
Table 5 and Table 6 introduce the Luc2 expression of the co-cultures of OVCAR-3 and 
Jurkat cells at 3 and 6 hours. 
Table 5. Luc2 Expression by Target Cells' Co-cultured with Effector Cells Expressing 















CCR5- / CCL5- 9329 
 
1860 14849 220 
CCR5+ / CCL5- 12356 
 
4915 20516 1738 
CCR5+ / CCL5+ 2604 297 2498 311 
 
Table 6. Luc2 Expression by Target Cells' Co-cultured with Effector Cells Expressing 















CCR7-/CCL19- 16267 1770 1629 
 
1467 
CCR7+/CCL19- 26871 2687 32467 2502 
CCR7+/CCL19+ 4627 394 3760 
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